Discussion on critical points for a tailored therapy to cure hepatitis C virus infection

摘要: Hepatitis C virus (HCV) infects around 71 million people worldwide and in 2018 it is still a major health problem. Since 2011, anti-HCV therapy with availability of direct-acting antiviral drugs has revolutionized the clinical response paved way to eradication strategies. However, despite high rate sustained virological response, treatment failure may occur limited percentage patients, possibly due resistance-associated substitutions (RASs), either emergent or pre-existent even minority viral populations. Clearly this problem impair success With background, several questions marks exist HCV treatment, including whether pan-genotypic treatments complete effectiveness any conditions really outside trials, actual cost-effectiveness genotyping testing, utility RAS detection quasispecies by next generation sequencing approach. In review, we describe these critical points discussing recent literature data our research experience.